21 CFR Part 211 is the FDA’s Current Good Manufacturing Practice (cGMP) rulebook for finished pharmaceuticals, and it governs every step a manufacturer takes from receiving raw ingredients through packaging, labeling, warehousing, and distribution of drug products intended for humans or animals.1eCFR. 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals A failure to follow any provision makes the drug legally adulterated under 21 U.S.C. 351, which opens the door to FDA seizures, injunctions, and criminal prosecution. Positron emission tomography (PET) drugs are the notable carve-out; they are regulated under Part 212 instead.
What Part 211 Covers
The regulation is organized into eleven subparts, each aimed at a different link in the manufacturing chain: organization and personnel, buildings and facilities, equipment, control of components and containers, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, and returned or salvaged drug products. The subparts overlap on purpose. A single batch of drug product has to satisfy all of them before it can be released for sale.
The Quality Control Unit and Personnel
Every facility must have a quality control unit with the authority to approve or reject all components, containers, closures, in-process materials, packaging, labeling, and finished drug products.2eCFR. 21 CFR Part 211 Subpart B – Organization and Personnel Nothing moves forward without its sign-off, and it also reviews production records to confirm each batch was made correctly.
Anyone involved in manufacturing must have education, training, and experience appropriate for their duties. Personnel wear clean clothing and, where needed, protective coverings for the head, face, hands, and arms to prevent contaminating the product.3eCFR. 21 CFR 211.28 – Personnel Responsibilities A visible illness or open wound that could affect product safety keeps a worker away from direct product contact until the condition resolves. Limited-access areas are restricted to authorized personnel only.
Facility and Equipment Requirements
Manufacturing buildings must be the right size, construction, and location to allow proper cleaning, maintenance, and orderly operations, with enough space to prevent mix-ups between components, containers, labels, in-process materials, and finished products.4eCFR. 21 CFR 211.42 – Design and Construction Features The layout has to separate or clearly define the areas used for receiving and quarantine, storage of rejected materials, manufacturing and processing, packaging and labeling, quarantine before release, storage of released product, and laboratory operations.
Aseptic processing carries stricter demands: smooth, cleanable surfaces on floors, walls, and ceilings; temperature and humidity control; HEPA-filtered air under positive pressure; and environmental monitoring. One rule allows no flexibility. Penicillin must be manufactured in facilities completely separate from those used for other human drug products, because trace penicillin contamination can trigger severe allergic reactions.
Equipment must be appropriately designed, sized, and located, and it must be cleaned, maintained, and where necessary sanitized or sterilized at suitable intervals.5eCFR. 21 CFR Part 211 Subpart D – Equipment Cleaning schedules are documented so residues from one batch cannot carry into the next. Automatic, mechanical, and electronic equipment, computers included, must be calibrated, inspected, or checked according to a written program, with records kept.6eCFR. 21 CFR 211.68 – Automatic, Mechanical, and Electronic Equipment Only authorized personnel can change master production records or other data in a computer system, input and output must be verified, and backups must be maintained and protected. Where automation handles a step that would otherwise need a worker plus a verifier, the automation can satisfy both roles as long as someone checks that the equipment performed correctly.
Incoming Materials: Quarantine, Test, Release
Every raw material and packaging item must go through a written receipt-and-release procedure before it touches the line.7eCFR. 21 CFR Part 211 Subpart E – Control of Components and Drug Product Containers and Closures On arrival, materials go into quarantine and stay there until the quality control unit samples and tests them. Each lot must undergo at least one identity test, and every component must be tested for purity, strength, and quality against written specifications. Sampling depth depends on the supplier’s history and the statistical confidence needed. Any lot that fails specifications must be rejected.
This quarantine-test-release cycle is where most supply chain problems get caught. Skipping or shortcutting it is one of the most common cGMP violations the FDA cites during inspections.
Production, Yield, and Reprocessing
Written procedures cover every production and process control step, drafted by the relevant organizational units and approved by the quality control unit.8eCFR. 21 CFR 211.100 – Written Procedures; Deviations They must be followed and documented in real time. Any deviation must be recorded and justified. An undocumented deviation, even one with a fine outcome, is itself a cGMP violation.
At the end of each appropriate manufacturing phase, the facility calculates the actual yield and the percentage of theoretical yield. One person calculates; a second independently verifies.9eCFR. 21 CFR Part 211 Subpart F – Production and Process Controls A yield outside the established acceptable range triggers a mandatory investigation.
Reprocessing a batch that failed to meet standards is allowed only under tight controls. Written procedures must describe the reprocessing system and the steps needed to bring the batch back into conformity, and the quality control unit must review and approve.10eCFR. 21 CFR 211.115 – Reprocessing The reprocessed material then has to pass the same testing a normal batch would face.11eCFR. 21 CFR 211.165 – Testing and Release for Distribution Production of different drug products must be physically or spatially separated, and active ingredients and additives must be weighed and measured with precision and verified.
Packaging and Labeling Safeguards
Labeling is one of the highest-risk points in pharmaceutical manufacturing, because getting the wrong label on a product can cause a patient to take the wrong drug or wrong dose. Part 211 stacks several controls on top of each other.
All labeling and packaging materials must be sampled and examined or tested on receipt and again before use.12eCFR. 21 CFR 211.122 – Materials Examination and Usage Criteria Labels for each different product, strength, dosage form, or quantity are stored separately with clear identification, and access is restricted. Outdated or obsolete labels must be destroyed. Gang-printed labeling (multiple products on the same sheet) is prohibited unless the labels are adequately differentiated by size, shape, or color.
When cut labeling is used for immediate containers, the facility has to apply at least one special control: dedicated packaging lines per product strength, electronic 100-percent label verification, or full visual inspection with independent verification by a second person. Labels issued for a batch must be examined for identity and conformity to the master production record before use.13eCFR. 21 CFR 211.125 – Labeling Issuance After packaging, labels issued must be reconciled against labels used and returned; a discrepancy outside preset limits triggers an investigation. Excess labeling bearing lot or control numbers must be destroyed.
Before a packaging run begins, the area must be inspected to confirm that all products and materials from previous operations have been removed.14eCFR. 21 CFR 211.130 – Packaging and Labeling Operations This line clearance step prevents the most dangerous packaging error: a leftover label from a previous batch ending up on the current product. Each drug product must carry a lot or control number that allows the manufacturing and control history to be traced.
Tamper-Evident Packaging for OTC Products
Over-the-counter drug products sold at retail must use tamper-evident packaging with indicators or barriers that give visible evidence of interference.15eCFR. 21 CFR 211.132 – Tamper-Evident Packaging Requirements for Over-the-Counter (OTC) Human Drug Products The design must be distinctive enough that it cannot easily be duplicated with common materials. Two-piece hard gelatin capsules must be sealed using an accepted tamper-evident technology. The retail package must carry a prominent statement identifying the tamper-evident features, placed so it remains visible even if the feature itself has been breached. Aerosols and ammonia inhalants in crushable glass ampules are among the products exempt from the labeling statement requirements.
Holding, Distribution, and Traceability
Written warehousing procedures must keep finished products in quarantine until the quality control unit releases them, and storage conditions (temperature, humidity, light) cannot be allowed to degrade the drug.16eCFR. 21 CFR Part 211 Subpart H – Holding and Distribution Distribution follows a first-in, first-out system, with temporary deviations allowed when appropriate. The facility must maintain a tracking system that can readily identify where each lot was shipped. If a quality problem surfaces after distribution, the manufacturer needs to know exactly which customers received the affected lot.
Laboratory Testing, Stability, and Expiration Dates
Laboratories must establish scientifically sound specifications, sampling plans, and test procedures, all approved by the quality control unit.17eCFR. 21 CFR Part 211 Subpart I – Laboratory Controls Before any batch ships, the lab must confirm it meets final specifications, including verifying the identity and strength of each active ingredient.11eCFR. 21 CFR 211.165 – Testing and Release for Distribution Products required to be free of harmful microorganisms undergo appropriate microbiological testing. Test methods themselves must be validated for accuracy, sensitivity, specificity, and reproducibility.
Every drug product must have a written stability testing program that evaluates how the product holds up over time. The results drive the label’s storage conditions and the assigned expiration date. Testing uses the same container-closure system as the commercial product, and drugs meant to be reconstituted at dispensing are tested both before and after reconstitution. Expiration dates appear on the labeling and are tied to the labeled storage conditions.18eCFR. 21 CFR 211.137 – Expiration Dating Homeopathic drug products are exempt from expiration dating, as are allergenic extracts labeled “No U.S. Standard of Potency” and certain OTC products stable for at least three years.
Out-of-Specification Investigations
When a batch or any of its components fails to meet specifications, the facility must conduct a thorough investigation, even if the batch has already been distributed.19eCFR. 21 CFR 211.192 – Production Record Review The investigation cannot stop at the failed batch. It must extend to other batches of the same product and to other products that may have been affected by the same failure. A written record of the investigation, its conclusions, and follow-up actions is required. Incomplete or superficial investigations are a recurring finding during FDA inspections.
Records: The Documentation Backbone
Every drug product must have a master production and control record that specifies its formula and full manufacturing process. For every lot, a batch production record documents each significant step: dates, major equipment used, specific identification of each batch of components, weights and measures, in-process and laboratory test results, actual yield and percentage of theoretical yield, and the identity of personnel who performed or checked each step.20eCFR. 21 CFR 211.188 – Batch Production and Control Records
Distribution records track where each lot was sent, which is the data needed for a recall. Written procedures must cover complaint handling, written or oral.21eCFR. 21 CFR 211.198 – Complaint Files Any complaint suggesting a possible failure to meet specifications is reviewed by the quality control unit, which decides whether a full investigation is needed. The complaint record includes the product name and strength, lot number, complainant, nature of the complaint, and the reply. Complaints involving serious and unexpected adverse drug experiences must be reported to the FDA.
Records for drug products with expiration dates must be kept at least one year past the batch’s expiration.22eCFR. 21 CFR 211.180 – General Requirements OTC products exempt from expiration dating follow a different rule: three years after distribution. The same distinction runs through component, container, closure, and labeling records. Complaint records must be kept whichever is longer, one year past the product’s expiration date or one year after receipt; for exempt OTC products, three years after distribution.
When records are kept electronically, 21 CFR Part 11 applies on top of Part 211.23eCFR. 21 CFR Part 11 – Electronic Records; Electronic Signatures Part 11 requires validated computer systems, audit trails, and electronic signatures that are uniquely tied to individual users and linked to their records in a way that prevents copying or transfer to falsify a different record.
Returned and Salvaged Drug Products
Products that come back from the market must be identified, held, and examined. Destruction is the default. A returned product can only be reprocessed or placed back into distribution if examination, testing, or other investigation proves it still meets appropriate standards. Salvaged products (those exposed to events like fire, flood, or accident) face even more scrutiny, because the conditions they went through are inherently suspect.
What Happens When a Manufacturer Violates Part 211
Enforcement usually begins with an FDA Form 483 at the close of an inspection, listing observed cGMP deficiencies. If the manufacturer fails to address them adequately, a Warning Letter often follows. Warning Letters are public and can damage a company’s standing with customers and with regulators in other countries.
When voluntary compliance fails, the FDA has three federal court remedies. It can seek an injunction under 21 U.S.C. 332, which authorizes federal district courts to restrain ongoing violations of the FD&C Act and can effectively shut down a facility until compliance is demonstrated.24Office of the Law Revision Counsel. 21 USC 332 – Injunction Proceedings It can seize adulterated drug products anywhere in interstate commerce through a court action under 21 U.S.C. 334.25Office of the Law Revision Counsel. 21 USC 334 – Seizure And it can pursue criminal charges.
Criminal penalties scale with history and intent. A first violation carries up to one year in prison and a fine of up to $1,000. A repeat offense, or any violation committed with intent to defraud or mislead, raises the maximum to three years in prison and a $10,000 fine. Certain prescription drug marketing violations involving knowing illegal conduct carry up to ten years in prison and a $250,000 fine. Civil penalties can reach $1,000,000 per violation for manufacturers whose representatives are convicted of illegal drug sample distribution after a second conviction within a ten-year period.26Office of the Law Revision Counsel. 21 USC 333 – Penalties